Stock listing
gettex:AI10 Biofrontera Inc. Aktie
German listing (gettex) of Biofrontera Inc. · home listing NASDAQ:BFRI
Follow Biofrontera Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:BFRI
$0.53 USD -0.07 (-11.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BFRI
- Day range
- $0.53 – $0.588 USDNov 20, 2026
- Volume
- 195,905 sharesNov 20, 2026
- Market cap
- $9.51M USDAt the close on Nov 20, 2026 · price × 17.95M shares outstanding
- 52-week range
- $0.53 – $1.66 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $537,536 USDMedian day 302,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BFRI · Home | $0.53 USD | -0.07 (-11.6%) | 195,905 | $0.57 | $0.588 | $0.53 | $0.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BFRI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.53 | -0.07 | -11.6% | $0.57 | $0.588 | $0.53 | 195,905 | |
| $0.60 | +0.006 | +1.1% | $0.602 | $0.66 | $0.581 | 130,932 | |
| $0.593 | +0.023 | +4.1% | $0.55 | $0.675 | $0.541 | 197,341 | |
| $0.57 | -0.13 | -18.6% | $0.70 | $0.70 | $0.57 | 401,738 | |
| $0.70 | -0.226 | -24.4% | $0.96 | $0.96 | $0.683 | 876,000 | |
| $0.926 | -0.012 | -1.3% | $0.938 | $0.94 | $0.912 | 131,400 | |
| $0.938 | +0.01 | +1.1% | $0.94 | $0.94 | $0.90 | 105,800 | |
| $0.928 | +0.04 | +4.5% | $0.90 | $0.94 | $0.888 | 156,700 | |
| $0.888 | +0.06 | +7.2% | $0.84 | $0.907 | $0.81 | 229,600 | |
| $0.828 | +0.02 | +2.5% | $0.82 | $0.84 | $0.81 | 208,100 | |
| $0.808 | -0.096 | -10.6% | $0.906 | $0.907 | $0.80 | 148,600 | |
| $0.904 | +0.014 | +1.6% | $0.889 | $0.93 | $0.845 | 194,200 | |
| $0.89 | +0.02 | +2.3% | $0.90 | $0.901 | $0.852 | 69,500 | |
| $0.87 | -0.003 | -0.3% | $0.873 | $0.95 | $0.854 | 75,900 | |
| $0.873 | -0.059 | -6.3% | $0.94 | $0.94 | $0.849 | 302,400 | |
| $0.932 | +0.046 | +5.2% | $0.864 | $0.95 | $0.864 | 145,600 | |
| $0.886 | +0.046 | +5.5% | $0.849 | $0.886 | $0.815 | 141,800 | |
| $0.84 | +0.018 | +2.2% | $0.847 | $0.863 | $0.801 | 94,300 | |
| $0.822 | +0.033 | +4.2% | $0.79 | $0.826 | $0.78 | 110,000 | |
| $0.789 | +0.008 | +1.0% | $0.799 | $0.812 | $0.78 | 112,900 | |
| $0.781 | -0.019 | -2.4% | $0.83 | $0.83 | $0.781 | 160,100 | |
| $0.80 | -0.004 | -0.5% | $0.80 | $0.81 | $0.80 | 130,300 | |
| $0.804 | -0.002 | -0.2% | $0.823 | $0.83 | $0.80 | 71,900 | |
| $0.806 | -0.016 | -1.9% | $0.85 | $0.85 | $0.79 | 150,600 | |
| $0.822 | -0.025 | -3.0% | $0.881 | $0.92 | $0.822 | 203,700 | |
| $0.847 | +0.017 | +2.0% | $0.82 | $0.882 | $0.82 | 275,900 | |
| $0.83 | -0.062 | -7.0% | $0.885 | $0.89 | $0.82 | 347,400 | |
| $0.892 | -0.033 | -3.6% | $0.927 | $0.94 | $0.87 | 319,700 | |
| $0.925 | -0.045 | -4.6% | $0.973 | $1.00 | $0.925 | 140,200 | |
| $0.97 | +0.051 | +5.5% | $0.925 | $1.01 | $0.91 | 275,200 | |
| $0.919 | -0.016 | -1.7% | $0.936 | $0.95 | $0.882 | 231,600 | |
| $0.935 | +0.003 | +0.3% | $0.924 | $0.98 | $0.91 | 278,800 | |
| $0.932 | +0.041 | +4.6% | $0.88 | $0.948 | $0.86 | 390,300 | |
| $0.891 | -0.124 | -12.2% | $1.00 | $1.00 | $0.88 | 720,900 | |
| $1.015 | -0.025 | -2.4% | $1.11 | $1.12 | $1.00 | 334,700 | |
| $1.04 | -0.04 | -3.7% | $1.06 | $1.07 | $1.02 | 340,900 | |
| $1.08 | -0.01 | -0.9% | $1.11 | $1.14 | $1.07 | 284,000 | |
| $1.09 | -0.04 | -3.5% | $1.10 | $1.14 | $1.08 | 258,100 | |
| $1.13 | -0.05 | -4.2% | $1.16 | $1.17 | $1.09 | 383,800 | |
| $1.18 | -0.02 | -1.7% | $1.20 | $1.23 | $1.16 | 247,100 | |
| $1.20 | +0.05 | +4.3% | $1.16 | $1.225 | $1.14 | 280,500 | |
| $1.15 | -0.02 | -1.7% | $1.17 | $1.18 | $1.122 | 288,900 | |
| $1.17 | +0.01 | +0.9% | $1.16 | $1.18 | $1.11 | 476,300 | |
| $1.16 | -0.16 | -12.1% | $1.32 | $1.32 | $1.14 | 918,800 | |
| $1.32 | +0.08 | +6.5% | $1.29 | $1.33 | $1.27 | 376,200 | |
| $1.24 | +0.03 | +2.5% | $1.22 | $1.29 | $1.22 | 573,400 | |
| $1.21 | +0.02 | +1.7% | $1.22 | $1.24 | $1.18 | 384,600 | |
| $1.19 | -0.17 | -12.5% | $1.33 | $1.36 | $1.17 | 1,476,600 | |
| $1.36 | -0.19 | -12.3% | $1.57 | $1.57 | $1.355 | 2,365,600 | |
| $1.55 | +0.09 | +6.2% | $1.54 | $1.62 | $1.50 | 1,456,100 | |
| $1.46 | -0.08 | -5.2% | $1.53 | $1.555 | $1.36 | 1,645,700 | |
| $1.54 | -0.02 | -1.3% | $1.57 | $1.61 | $1.525 | 532,900 | |
| $1.56 | -0.05 | -3.1% | $1.64 | $1.66 | $1.54 | 840,200 | |
| $1.61 | +0.10 | +6.6% | $1.52 | $1.63 | $1.52 | 631,300 | |
| $1.51 | -0.01 | -0.7% | $1.51 | $1.559 | $1.48 | 549,500 | |
| $1.52 | -0.015 | -1.0% | $1.525 | $1.60 | $1.50 | 581,200 | |
| $1.535 | +0.005 | +0.3% | $1.54 | $1.56 | $1.505 | 400,700 | |
| $1.53 | -0.06 | -3.8% | $1.555 | $1.60 | $1.50 | 744,300 | |
| $1.59 | +0.10 | +6.7% | $1.53 | $1.61 | $1.51 | 837,000 | |
| $1.49 | -0.04 | -2.6% | $1.555 | $1.57 | $1.475 | 436,200 | |
| $1.53 | +0.02 | +1.3% | $1.54 | $1.60 | $1.49 | 542,900 | |
| $1.51 | +0.05 | +3.4% | $1.47 | $1.52 | $1.42 | 439,887 | |
| $1.46 | -0.02 | -1.4% | $1.48 | $1.55 | $1.41 | 995,019 | |
| $1.48 | 0.00 | 0.0% | $1.48 | $1.52 | $1.441 | 446,300 | |
| $1.48 | +0.06 | +4.2% | $1.43 | $1.50 | $1.40 | 526,100 |
Splits
1 split · NASDAQ:BFRI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- gettex:AI10
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 13, 2026
Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth
Latest earnings call · Nov 13, 2026
Biofrontera (NASDAQ:BFRI) Q3 2026 Earnings Call
Replay and transcript
Latest news
Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth
Nov 13, 2026
Closed $0.70 (-24.4%) on Nov 13, 2026
Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026
Nov 6, 2026
Closed $0.888 (+7.2%) on Nov 9, 2026
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
Oct 8, 2026
Closed $0.919 (-1.7%) on Oct 8, 2026
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Sep 14, 2026
Closed $1.36 (-12.3%) on Sep 14, 2026
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
Aug 13, 2026
Closed $1.26 (+0.8%) on Aug 13, 2026
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
Aug 5, 2026
Closed $1.25 (+0.8%) on Aug 6, 2026
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
May 21, 2026
Closed $0.779 (-3.5%) on May 21, 2026
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
May 14, 2026
Closed $0.989 (+3.0%) on May 14, 2026
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
May 13, 2026
Closed $0.96 (-5.0%) on May 13, 2026
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
May 8, 2026
Closed $1.11 (-3.5%) on May 11, 2026
Biofrontera Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 21 in the last 12 months · 138 in all · newest Nov 13, 2026 · oldest 2021
- Calls
- 22 calls with a replay · 22 with a transcript · latest Nov 13, 2026
Where Biofrontera Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BFRI · Home listing | NASDAQ | United States | USD |
| BOATS:BFRI | BOATS | United States | USD |
| gettex:AI10 · This page | gettex | Germany | EUR |
| Munich:AI10 | Munich | Germany | EUR |
| LS Exchange:A3EFRZ | LS Exchange | Germany | EUR |
Valuation
EV/sales 0.3× against a median of 0.6×: 4th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $13.83M USD
- P/E
- Loss
- EV/sales
- 0.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 84.6%
- Operating margin
- −14.1%
- Net margin
- −12.7%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.96
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Biofrontera Inc. · NASDAQ:BFRI | US$9.51M | US$13.83M | n/a | 0.3× | n/a | n/a | −12.7% | n/a | 1.96 |
| Botanix Pharmaceuticals Limited · ASX:BOT | US$14.62M | US$133,810 | n/a | 0.0× | n/a | 0.3× | −202.2% | 0.2× | n/a |
| Bal Pharma Limited · NSE:BALPHARMA | US$14.30M | US$14.30M | 18.4× | 0.4× | 3.9× | 1.6× | 2.1% | 0.0× | n/a |
| Daesung Microbiological Laboratories Co., Ltd. · KRX:036480 | US$14.23M | US$18.69M | 54.3× | 1.0× | 13.5× | 0.6× | 1.4% | 0.4× | n/a |
| Turk Ilac ve Serum Sanayi AS · BIST:TRILC | US$14.16M | US$22.15M | 7.7× | 0.2× | 0.6× | 0.4× | 1.6% | 0.2× | n/a |
| PT Phapros Tbk · IDX:PEHA | US$12.79M | US$41.58M | 4.5× | 0.7× | 4.6× | 0.5× | 5.0% | 1.5× | n/a |
| PT Ikapharmindo Putramas Tbk · IDX:IKPM | US$11.81M | US$10.76M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| Alpa Laboratories Limited · NSE:ALPA | US$11.33M | US$11.33M | 24.0× | 0.9× | 12.2× | 0.6× | 3.8% | 0.0× | n/a |
| Advicenne SA · EURONEXT:ALDVI | US$10.53M | US$32.08M | n/a | 4.9× | n/a | n/a | −158.7% | n/a | n/a |
| Optimi Health Corp. · CSE:OPTI | US$9.18M | US$67,058 | n/a | 0.6× | n/a | 0.8× | n/a | 0.0× | 1.08 |
| ChoA Pharmaceutical Co., Ltd. · KRX:034940 | US$6.59M | US$6.89M | n/a | 0.1× | n/a | 0.3× | −4.6% | 0.1× | n/a |
| Median of the others | US$12.30M | US$12.81M | 18.4× | 0.6× | 4.6× | 0.6× | 1.5% | 0.1× | 1.08 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.18 · 1 analyst
- Revenue, year to Dec 2026
- 46.15M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Hermann Luebbert | CEO & Chairman |
| Fred Leffler | Chief Financial Officer |
| Daniel Hakansson | Senior Corporate Counsel |
| Erica Gates | Vice President of Finance |
| Jon Lyons | Vice President of Scientific & Medical Affairs |
| Samantha Widdicombe | Senior Vice President of Sales & Strategic Accounts |
| Wiebke Meyer-Wendt | Vice President of Global Quality & Research |
| George Jones | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Hermann Luebbert | CEO & Chairman |
| Heikki Lanckriet | Board Member |
| John J. Borer | Board Member |
| Kevin D. Weber | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Biofrontera (NASDAQ:BFRI) Q3 2026 Earnings Call | Fri, Nov 13, 2026 · 10:00 AM ET | Replay |
| Biofrontera (NASDAQ:BFRI) Q2 2026 Earnings Call | Thu, Aug 13, 2026 · 10:00 AM ET | Replay |
| Biofrontera (NASDAQ:BFRI) Q1 2026 Earnings Call | Thu, May 14, 2026 · 11:00 AM ET | Replay |
| Biofrontera (NASDAQ:BFRI) Q4 2025 Earnings Call | Thu, Mar 19, 2026 · 10:00 AM ET | Replay |
| Biofrontera (NASDAQ:BFRI) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 10:00 AM ET | Replay |
| Biofrontera (NASDAQ:BFRI) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 10:00 AM ET | Replay |
| Biofrontera (NASDAQ:BFRI) Q1 2025 Earnings Call | Fri, May 16, 2025 · 10:00 AM ET | Replay |
| Biofrontera (NASDAQ:BFRI) Q4 2024 Earnings Call | Fri, Mar 21, 2025 · 10:00 AM ET | Replay |
| Biofrontera (NASDAQ:BFRI) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 10:00 AM ET | Replay |
| Biofrontera (NASDAQ:BFRI) Q2 2024 Earnings Call | Thu, Aug 15, 2024 · 10:00 AM ET | Replay |
All 22 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · Before open | −24.4% |
| Q2 2026 | Aug 13, 2026 · Before open | +0.8% |
| Q1 2026 | May 14, 2026 | −16.7% |
| Q4 2025 | Mar 19, 2026 · After close | +1.7% |
| Q3 2025 | Nov 12, 2025 · After close | −8.6% |
| Q2 2025 | Aug 13, 2025 · After close | +1.7% |
| Q1 2025 | May 15, 2025 · After close | −7.2% |
| Q4 2024 | Mar 13, 2025 · After close | −1.5% |
| Q3 2024 | Nov 13, 2024 · After close | −15.4% |
| Q2 2024 | Aug 14, 2024 · After close | +1.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | −9.9% |
| Q4 2023 | Mar 15, 2024 · After close | −18.7% |
| Q3 2023 | Nov 9, 2023 · After close | −2.6% |
| Q2 2023 | Aug 11, 2023 · Before open | −3.8% |
| Q1 2023 | May 12, 2023 · After close | +0.5% |
| Q4 2022 | Mar 8, 2023 · After close | −10.2% |
| Q3 2022 | Nov 14, 2022 · Before open | 0.0% |
| Q2 2022 | Aug 12, 2022 · Before open | +2.9% |
| Q1 2022 | Apr 8, 2022 · Before open | +14.4% |
| Quarter to Sep 30, 2021 | Nov 30, 2021 · Before open | −15.6% |
Financings
| Raise | Date |
|---|---|
| Private placement of investment Closed: US$11M raised Buyers: Rosalind Advisors, Inc. (Co-led the $11 million investment); AIGH Capital Management LLC (Co-led the $11 million investment) Use of proceeds: Funding the purchase of all U.S. Ameluz and RhodoLED assets from Biofrontera AG | Oct 23, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$5.00 a unit on Oct 28, 2021.
- Price
- US$5.00 a unit
- Units offered
- 3,600,000 units
- Offering size
- US$18 million
- Underwriters' option
- Up to 540,000 more units
- Listing
- BFRI on the Nasdaq Capital Market
- Underwriters
- Roth Capital Partners, The Benchmark Company · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 7, 2021 |
| Filed publicly | Jul 6, 2021 |
| Amended 11 times | Newest Oct 26, 2021 |
| Shares registered with an exchange | Oct 20, 2021 |
| Declared effective by the SEC | Oct 28, 2021 |
| Final prospectus, with the price | Nov 1, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 1, 2021 |
| FWP · Free writing prospectus | Oct 29, 2021 |
| EFFECT · Notice that a registration is effective | Oct 28, 2021 |
| CERT · Exchange's certificate of listing | Oct 28, 2021 |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Oct 27, 2021 |
| CORRESP · Letter to the SEC | Oct 27, 2021 |
| CORRESP · Letter to the SEC | Oct 27, 2021 |
| S-1/A · Registration statement, amended | Oct 26, 2021 |
| CORRESP · Letter to the SEC | Oct 20, 2021 |
| CORRESP · Letter to the SEC | Oct 20, 2021 |
All 50 filings
Open IPO · From the cover of the final prospectus (424B4) filed Nov 1, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 41.7M | 37.3M | 34.1M | 28.7M | 24.1M | 18.8M | 26.2M |
| Cost of revenue | 8.90M | 18.6M | 17.4M | 15.2M | 12.7M | 9.07M | 12.4M |
| Gross profit | 32.8M | 18.7M | 16.6M | 13.5M | 11.4M | 9.78M | 13.8M |
| Research and development | 3.72M | 2.09M | 77.0K | 0 | |||
| Selling, general and administrative | 37.8M | 33.8M | 39.0M | 35.1M | 36.5M | 17.7M | 28.7M |
| Operating income | -11.3M | -17.2M | -22.7M | -18.6M | -25.2M | -9.61M | -14.9M |
| Depreciation and amortization | 138.0K | 421.0K | 600.0K | 101.0K | 122.0K | 144.0K | 667.0K |
| EBITDA | -11.2M | -16.8M | -22.1M | -18.5M | -25.1M | -9.46M | -14.3M |
| Interest expense | 452.0K | 2.11M | 220.0K | 12.0K | 344.0K | 2.87M | 2.16M |
| Income before tax | -10.5M | -17.7M | -20.1M | -608.0K | -37.7M | -10.9M | -10.9M |
| Income tax | 25.0K | 22.0K | 14.0K | 32.0K | 56.0K | 64.0K | 33.0K |
| Net income | -10.5M | -17.8M | -20.1M | -640.0K | -37.7M | -11.0M | -11.0M |
| Earnings per share, basic | -1.04 | -3.22 | -13.02 | -0.61 | -4.28 | -479.48 | -18.09 |
| Earnings per share, diluted | -1.04 | -3.22 | -13.02 | -0.61 | -4.28 | -479.48 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 6.39M | 5.91M | 1.34M | 17.2M | 24.5M | 8.08M | 7.30M |
| Short-term investments | 9.00K | 7.00K | 78.0K | 10.5M | 0 | ||
| Receivables | 7.29M | 5.32M | 5.16M | 7.41M | 3.78M | 3.29M | 4.79M |
| Inventory | 1.43M | 6.65M | 10.9M | 7.17M | 4.46M | 7.09M | 10.5M |
| Current assets | 18.1M | 20.7M | 23.1M | 43.1M | 46.4M | 19.6M | 23.5M |
| Property, plant and equipment | 2.16M | 80.0K | 134.0K | 204.0K | 267.0K | 370.0K | 503.0K |
| Total assets | 28.6M | 22.1M | 27.9M | 50.9M | 53.2M | 24.1M | 28.8M |
| Accounts payable | 1.85M | 1.86M | 8.91M | 1.28M | 658.0K | 176.0K | 7.81M |
| Current liabilities | 11.9M | 12.0M | 18.1M | 20.9M | 13.8M | 4.42M | 11.7M |
| Long-term debt | 4.59M | 4.10M | 38.2M | ||||
| Total debt | 6.16M | 4.92M | 5.40M | 1.35M | 38.2M | ||
| Total liabilities | 18.1M | 17.7M | 23.1M | 27.0M | 41.9M | 18.3M | 58.9M |
| Shareholders' equity | 10.5M | 4.43M | 4.79M | 23.9M | 11.3M | 5.83M | -30.2M |
| Shares outstanding | 11.6M | 8.87M | 1.52M | 1.33M | 17.1M | 8.00M | 607.0K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -13.4M | -10.3M | -24.9M | -16.2M | -26.7M | -12.4M | -37.7M |
| Capital spending | -2.00K | -10.0K | -5.00K | -38.0K | -11.0K | -11.0K | -538.0K |
| Free cash flow | -13.4M | -10.3M | -24.9M | -16.2M | -26.7M | -12.4M | -38.2M |
| Cash from investing | 3.00M | -3.00K | 619.0K | -5.16M | -11.0K | -11.0K | 25.4M |
| Cash from financing | 10.8M | 14.8M | 8.41M | 14.0M | 43.2M | 13.2M | 16.4M |
| Change in cash | 487.0K | 4.56M | -15.9M | -7.33M | 16.5M | 825.0K | 4.12M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 25-NSE | Oct 30, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jul 22, 2026 | Offer document | SEC |
| 10-K/A · Annual report, amended | Jul 22, 2026 | Annual report | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 9, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2026 | Results | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 17, 2025 | Other filings | SEC |
| S-1 · Registration statement | Dec 5, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 8-K · Current report | Nov 7, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Oct 24, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 19, 2025 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 19, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 20, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 15, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 13, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 11, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Aug 5, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 25, 2025 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 25, 2025 | Big-stake notice | SEC |
| S-1 · Registration statement | Jul 16, 2025 | Offer document | SEC |
| 8-K/A · Current report, amended | Jul 16, 2025 | Current report | SEC |
| D | Jul 11, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Jul 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 11, 2025 | Current report | SEC |
| 8-K · Current report | Jun 3, 2025 | Current report | SEC |
| DEFR14A | Jun 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 23, 2025 | Current report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 18, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 21, 2025 | Results | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jan 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 22, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jan 21, 2025 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 20, 2024 | Big-stake notice | SEC |
| D | Dec 5, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 27, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 22, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| S-8 · Registration statement for employee plans | Nov 13, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 1, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 31, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 23, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 7, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Sep 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2024 | Current report | SEC |
| 8-K · Current report | Jun 14, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | May 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 8-K · Current report | May 22, 2024 | Current report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | May 10, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 8, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 8, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | May 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 3, 2024 | Current report | SEC |
| S-1 · Registration statement | May 2, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 30, 2024 | Current report | SEC |
| DEFR14A | Apr 30, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2024 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Apr 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Apr 17, 2024 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Apr 3, 2024 | Current report | SEC |
| 8-K · Current report | Mar 26, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Mar 21, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Mar 20, 2024 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Mar 20, 2024 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Mar 20, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Mar 20, 2024 | Big-stake notice | SEC |
| S-1/A · Registration statement, amended | Mar 19, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 18, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 15, 2024 | Results | SEC |
| 10-K · Annual report | Mar 15, 2024 | Annual report | SEC |
| SC 13G · Big-stake notice | Mar 15, 2024 | Big-stake notice | SEC |
| S-1 · Registration statement | Mar 8, 2024 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Mar 8, 2024 | Meeting notice | SEC |
| D | Mar 5, 2024 | Other filings | SEC |
| 8-K · Current report | Feb 23, 2024 | Material contract | SEC |
| 8-K · Current report | Feb 20, 2024 | Material contract | SEC |
| RW · Request to withdraw a registration | Feb 20, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2024 | Current report | SEC |
| 8-K · Current report | Feb 5, 2024 | Current report | SEC |
| 8-K · Current report | Feb 2, 2024 | Material contract | SEC |
| S-1/A · Registration statement, amended | Jan 29, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 25, 2024 | Current report | SEC |
| S-1 · Registration statement | Jan 16, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 11, 2024 | Results | SEC |
| 8-K/A · Current report, amended | Jan 9, 2024 | Current report | SEC |
| 8-K · Current report | Jan 3, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 28, 2023 | Material contract | SEC |
| 8-K · Current report | Dec 27, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Dec 15, 2023 | Material contract | SEC |
| 8-K · Current report | Nov 29, 2023 | Current report | SEC |
| DEF 14A · Proxy statement | Nov 17, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 8-K · Current report | Nov 2, 2023 | Material contract | SEC |
| 424B4 · Prospectus | Nov 1, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 31, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 27, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Oct 26, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Oct 13, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Oct 13, 2023 | Offer document | SEC |
| 8-K · Current report | Oct 13, 2023 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Oct 11, 2023 | Other filings | SEC |
| 8-K · Current report | Oct 10, 2023 | Current report | SEC |
| S-1 · Registration statement | Oct 4, 2023 | Offer document | SEC |
| 8-K · Current report | Oct 4, 2023 | Results | SEC |
| 8-K · Current report | Oct 3, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 22, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jul 13, 2023 | Results | SEC |
| 8-K · Current report | Jul 12, 2023 | Management or board change | SEC |
| 8-K · Current report | Jul 3, 2023 | Current report | SEC |
| 8-K · Current report | Jun 20, 2023 | Current report | SEC |
| 8-K · Current report | Jun 2, 2023 | Current report | SEC |
| 8-K · Current report | Jun 1, 2023 | Current report | SEC |
| 8-K · Current report | May 30, 2023 | Current report | SEC |
| 8-K · Current report | May 26, 2023 | Management or board change | SEC |
This page holds 200 of 369 filings. Open Filings
Cap table
Built by 6ix from Biofrontera Inc.’s releases · as of Nov 11, 2026
- Common shares
- 17,949,000
- Fully diluted
- 17,949,000
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 17,949,000 | Nov 11, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 17,949,000 |
| Sep 30, 2026 | 17,949,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Beth J Hoffman | Director · Since at least Nov 2, 2021 |
| Daniel Hakansson | Senior Corporate Counsel · Since at least Nov 5, 2026 |
| Erica Gates | Vice President of Finance · Since at least Oct 28, 2021 |
| Eugene Frederick Leffler | Chief Financial Officer · Since at least Jul 12, 2024 |
| Fred Leffler | Chief Financial Officer · Since at least Aug 13, 2026 |
| George Jones | Chief Commercial Officer · Since at least Aug 11, 2025 |
| Heikki Lanckriet | Board Member · Since at least Jul 3, 2023 |
| Hermann Luebbert | CEO & Chairman · Since at least Jul 22, 2025 |
| John J. Borer | Board Member · Since at least Nov 4, 2026 |
| John J Borer III | Director · Since at least Nov 2, 2021 |
All 14 people
| Person | Seat |
|---|---|
| Jon Lyons | Vice President of Scientific & Medical Affairs · Since at least Nov 4, 2026 |
| Kevin D. Weber | Board Member · Since at least Mar 2, 2022 |
| Samantha Widdicombe | Senior Vice President of Sales & Strategic Accounts · Since at least Nov 5, 2026 |
| Wiebke Meyer-Wendt | Vice President of Global Quality & Research · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Biofrontera Inc.